NA
CORT icon

Navellier & Associates’s Corcept Therapeutics CORT Stock Holding History

Navellier & Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-106,862
Closed -$1.86M – 279
2020
Q3 		$1.86M Buy
106,862
+43,518
+69% +$694K 0.41% 81
2020
Q2 		$1.06M Buy
+63,344
New +$890K 0.25% 95
2018
Q3 		– Sell
-114,041
Closed -$1.79M – 304
2018
Q2 		$1.79M Buy
114,041
+1,951
+2% +$33.9K 0.25% 116
2018
Q1 		$1.84M Buy
112,090
+11,352
+11% +$210K 0.28% 109
2017
Q4 		$1.82M Buy
100,738
+62,158
+161% +$1.13M 0.34% 95
2017
Q3 		$745K Buy
+38,580
New +$575K 0.14% 112

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Navellier & Associates's CORT Position: Q4 2020 in Review

Navellier & Associates sold out of Corcept Therapeutics (CORT) in Q4 2020, closing a stake of 106,862 shares — an estimated $1.86M sold.

Navellier & Associates first reported a position in CORT in Q3 2017 and held it in 6 quarters. The position peaked at $1.86M in Q3 2020. 226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

  • Navellier & Associates reported no remaining Corcept Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Navellier & Associates sold 106,862 Corcept Therapeutics shares in Q4 2020, an estimated $1.86M.
  • Navellier & Associates first reported a position in Corcept Therapeutics in Q3 2017 and held it in 6 quarters.
  • Navellier & Associates's Corcept Therapeutics position peaked at $1.86M in Q3 2020.
  • 226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Navellier & Associates's 13F filing for Q4 2020, filed 5 Feb 2021.